Trial purpose
Cancer treatment
Tumor type
Haematological
Age
18+
Clinical summary
Summary
This study is comparing the effectiveness of two different doses of targeted therapy (called ianalumab) comapred to placebo, when added to eltrombopag. Eligible participants will be randomly allocated to one of three treatment arms.
In Arm 1 (Experimental), participants will receive eltrombopag and lower dose ianalumab.
In Arm 2 (Experimental), participants will receive eltrombopag and higher dose ianalumab.
in Arm 2 (Placebo Comparator), participants will receive eltrombopag and placebo.
Eltrombopag will be administered as a film-coated tablet for oral use. Ianalumab and Placebo will be given as an intravenous (IV) infusion.
Conditions
This trial is treating patients with Primary Immune Thrombocytopenia
Eligibility
Inclusion
- Male or female patients aged 18 years and older on the day of signing the informed consent.
- A signed informed consent must be obtained prior to participation in the study.
- A diagnosis of primary ITP, with insufficient response to, or relapse after a first-line corticosteroid therapy ± IVIG.
- Platelet count <30 G/L and assessed need for treatment (per physician's discretion).
Exclusion
- ITP patients who received second-line ITP treatments (other than steroid therapy± IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (max one week) before screening are eligible.
- Patients with key lab abnormalities and patients with Evans syndrome or any other cytopenia
- Patients with history of clinically significant hematological disorders, or with marked altered hematologic parameters
- Patients with current or history of life-threatening bleeding
- Patient that are Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B surface Antigen (HBsAg)/ Hepatitis B core antibody (HBcAB)-positive
- Patients with known active or uncontrolled infection requiring systemic treatment during screening period
- Patients with hepatic impairment
- Patients with concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant medication
- Female patients who are pregnant or nursing
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Novartis Pharmaceuticals
Scientific Title
A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
More info for carers